VORETIGENE NEPARVOVEC (Luxturna®)
Clinical Indication
Vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations
Comments
Not yet reviewed
Date of classification
February 2020
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.